
European regulators have given their backing to a new eco-friendly inhaler that could help curb health care’s climate impact.
Drugmaker AstraZeneca said the new inhaler has a fraction of the carbon footprint of its existing model, which uses a gas propellant to deliver a dose of medicine to patients and is already available in the European Union for adults with chronic obstructive pulmonary disease (COPD).